Psychedelics biotech COMPASS Pathways’ (NASDAQ:CMPS) consolidated unaudited financial results for the second quarter 2023, ended June 30 are as follows:
-
Cash and cash equivalents totaled $148.2 million, compared to $143.2 million held in Dec. 31, 2022, and considering this 2023 quarter’s financing for a total $55.9 million in net cash.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased